Intraepithelial Neoplasia clinical trials

Explore recruiting intraepithelial neoplasia clinical trials.

Recruiting intraepithelial neoplasia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Intraepithelial Neoplasia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy of pre-surgical HPV9-valente vaccination in women treated with loop electrosurgical excision (LEEP) for high-grade cervical intraepithelial neoplasia (CIN2+) up to cervical cancer initially invasive (FIGO IA1) - HOPE 9 STUDY

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Concomitant HPV vaccination and HPV screening for rapid elimination of HPV infection and cervical cancer in Sweden

Sweden

Therapeutic use (Phase IV) EU CTIS Study details

A Registry-Based Extension of Protocol V503-001 in Countries with Centralized Cervical Cancer Screening Infrastructures to Evaluate the Long-Term Effectiveness, immunogenicity, and Safety of Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine as Administered to 16- to 26- Year- Old Women.

Norway, Sweden, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

Low dose TamOxifen and LifestylE changes for bReast cANcer prevenTion: a randomized phase II biomarker trial in subjects at increased risk (TOLERANT Study)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Intraepithelial Neoplasia trials by city

Intraepithelial Neoplasia in Toronto Intraepithelial Neoplasia in Vancouver Intraepithelial Neoplasia in Montreal Intraepithelial Neoplasia in Calgary Intraepithelial Neoplasia in Edmonton Intraepithelial Neoplasia in Ottawa Intraepithelial Neoplasia in Winnipeg Intraepithelial Neoplasia in Quebec City Intraepithelial Neoplasia in Hamilton Intraepithelial Neoplasia in Kitchener Intraepithelial Neoplasia in London Intraepithelial Neoplasia in Halifax Intraepithelial Neoplasia in New York Intraepithelial Neoplasia in Los Angeles Intraepithelial Neoplasia in Chicago Intraepithelial Neoplasia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease